Is Progyny (PGNY) Pricing Make Sense After Prolonged Share Price Slump?

• If you are wondering whether Progyny's current share price reflects its true worth, the recent performance gives a lot to think about.
• The stock last closed at US$16.60, with returns of a 6.7% decline over 7 days, 5.3% decline over 30 days, 35.5% decline year to date, 28.3% decline over 1 year, 46.8% decline over 3 years and 63.7% decline over 5 years.
• Recent coverage has focused on Progyny's position in the healthcare sector and how the share price trends compare with peers and the broader market. This context matters for investors who are reassessing what risks and opportunities are currently being priced into the stock.
• On Simply Wall St's valuation checks, Progyny records a valuation score of 3 out of 6. This sets up a closer look at different valuation methods and a final section that goes one step further to help you make sense of what that score really means.

Find out why Progyny's -28.3% return over the last year is lagging behind its peers.

Approach 1: Progyny Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business could be worth by projecting its future cash flows and discounting them back to today’s value. It is essentially asking what those future cash flows are worth in today’s dollars.

For Progyny, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $200.2 million. Analyst and extrapolated estimates then project free cash flow out over the next decade, with values such as $122.9 million in 2026 and $224.2 million in 2030, all in dollars and discounted back using Simply Wall St’s assumptions.

Adding up these discounted cash flows produces an estimated intrinsic value of about $69.98 per share under this DCF model. Compared with the recent share price of $16.60, the DCF output implies that Progyny is around 76.3% undervalued based on these inputs and assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Progyny is undervalued by 76.3%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Progyny.

Approach 2: Progyny Price vs Earnings

For a profitable company, the P/E ratio is a useful way to think about value because it links what you pay today to the earnings the business is already generating. Investors usually accept a higher or lower P/E depending on what they expect for future growth and how risky they think those earnings are.

Progyny currently trades on a P/E of 22.22x. That sits close to the broader Healthcare industry average P/E of 22.02x and above the peer group average of 18.19x. On the surface, this suggests the market is pricing Progyny slightly higher than peers, and roughly in line with the wider industry.

Simply Wall St’s “Fair Ratio” for Progyny is 21.81x. This is a proprietary estimate of what a reasonable P/E might be after accounting for factors such as earnings growth, profit margins, risks, market cap and the Healthcare industry context. Because it blends these elements, the Fair Ratio can give a more tailored view than a simple comparison with peers or the sector.

Compared with the Fair Ratio of 21.81x, Progyny’s current P/E of 22.22x is slightly higher. This points to the shares being modestly overvalued on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Progyny Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives bring the story you believe about Progyny together with the numbers by letting you link your view on future revenue, earnings and margins to a forecast, then to a Fair Value that can be compared with the current price.

On Simply Wall St’s Community page, Narratives are an accessible tool used by millions of investors to set out their own assumptions. For Progyny you can see, for example, one Narrative that ties a more cautious Fair Value of about US$21.00 to expectations for lower growth and a 21.4x future P/E, alongside another Narrative that points to a higher Fair Value of about US$32.00 based on stronger growth and a 22.7x future P/E. Each view updates automatically as new news or earnings data comes in to help you decide whether the price you see today lines up with the story you find more convincing.

Do you think there's more to the story for Progyny? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com